While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, existing options do not lead to favorable clinical outcomes in all patients.

By blocking P-glycoprotein 1, forskolin allowed for more daunorubicin to go inside the leukemia cells, making the chemotherapy much more potent. Dr. Maria Teresa Esposito, senior lecturer in ...

Forskolin, a plant-derived compound, shows surprising potential against one of the most aggressive forms of leukemia. Researchers discovered that it not only stops cancer cells from growing but also ...

A significant survival improvement finding for adults with newly diagnosed BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia appears in the New England Journal of Medicine. The practice ...

B-PLL is a rare subtype that’s more aggressive than other blood cancers and has a low survival rate. However, ongoing research and clinical trials may offer new treatment options to improve outcomes.

Phase II study of cladribine, low-dose cytarabine, and venetoclax, alternating with azacitidine and venetoclax, in higher-risk chronic myelomonocytic leukemia and myelodysplastic syndromes. This is an ...